NewsRadar
Home
Research
Products & Services
Online Data Service
Deals in Europe Report
Radar
Advanced Search
Add Company
Add Person
Customized Research
Weekly Newsletter
Online News
Events

Ablynx
Founded in 2001 in Ghent, Belgium, Ablynx is a biopharmaceutical company focused on the discovery and development of Nanobodies, a class of therapeutic proteins based on single-domain antibody fragments, for a range of serious and life-threatening human diseases. The company currently has over 170 employees. Ablynx completed a successful IPO on Euronext Brussels [ABLX] on 7 November 2007.

• Show past press releases
• Edit this company

ELEVATOR PITCH
Ablynx is building a diverse and broad portfolio of therapeutic Nanobodies® through these collaborations as well as through its own internal discovery programmes. Ablynx announced final Phase I data from its first programme, an anti-thrombotic (ALX-0081) in December 2007 and another programme, which is partnered, is in advanced preclinical development.

CONTACT INFORMATION
Address:
 
 
Phone:
Fax:
Web:
Contact:
 
 
Technologiepark 4
Gent-Zwijnaarde 9052
Belgium
+32 (0)9 262 00 00
+32 (0)9 262 00 01
http://www.ablynx.com
Ciska Vansteenkiste
+32 (0)9 262 00 00

COMPANY FACTS
Founded:Jul 2001
Founders:GIMV, VIB
CEO:Edwin Moses
CTO or technical lead:Josefin-Beate Holz, Chief Medical Officer
CFO or finance director:Wim Ottevaere
Head of Sales:
Head of Marketing:Eva-Lotta Allan

Stage:Public
Category:Biotechnology & Healthcare
Sector:Biopharmaceuticals
Employees:170
Profitability:Pre-revenue
Funding raised:Yes
Funding sought:Yes
Seeking Partnerships:Yes

NON-EXECUTIVE BOARD MEMBERS

  • Edwin Moses, Chairman
  • Frank Bulens, GIMV
  • Rudy Dekeyser, VIB
  • John Berriman
  • Denis Lucquin, Sofinnova
  • Ekaterina Smirnyagina , Alta Partners
  • Stephen Bunting , Abingworth
  • Ruth Devenyns, KBC

    KEY CUSTOMERS

  • Not Available

    KEY BUSINESS PARTNERS

  • Boehringer Ingelheim
  • Novartis
  • P&G Pharmaceuticals
  • Wyeth Pharmaceuticals

    KEY COMPETITORS

  • Not Available

    CAPITAL RAISED
    DateSizeInvestors
    To view this information you must be signed in and subscribed to the online dataservice, sign in here.

    To read more about the Online data service click here

    PUBLIC OFFERINGS
    DateTypeExchange
    Nov 2007InitialEuronext Brussels, First Market




  • Copyright © 1999-2010
    Test Publishing Limited. All rights reserved. Legal Information.